HEIP
VIVO

Hudson Edge Investment Partners’s Meridian Bioscience Inc VIVO Stock Holding History

Hudson Edge Investment Partners’s Portfolio VIVO Stock Details VIVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-18,762
Closed -$487K – 141
2022
Q1 		$487K Sell
18,762
-18,296
-49% -$435K 0.15% 121
2021
Q4 		$756K Buy
37,058
+8,966
+32% +$172K 0.23% 79
2021
Q3 		$540K Buy
+28,092
New +$560K 0.18% 118

Other funds holding VIVO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IC
Impactive Capital New York City, New York $1.38B AUM 1.92% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VLKIM
Van Lanschot Kempen Investment Management Amsterdam, Netherlands $11.4B AUM 16.77% 1-Year Est. Return

Hudson Edge Investment Partners's VIVO Position: Q2 2022 in Review

Hudson Edge Investment Partners sold out of Meridian Bioscience Inc (VIVO) in Q2 2022, closing a stake of 18,762 shares — an estimated $487K sold.

Hudson Edge Investment Partners first reported a position in VIVO in Q3 2021 and held it in 3 quarters. The position peaked at $756K in Q4 2021. 216 funds tracked by Wall St. Rank hold VIVO as of Q2 2022.

  • Hudson Edge Investment Partners reported no remaining Meridian Bioscience Inc position as of Q2 2022 after selling out during the quarter.
  • Hudson Edge Investment Partners sold 18,762 Meridian Bioscience Inc shares in Q2 2022, an estimated $487K.
  • Hudson Edge Investment Partners first reported a position in Meridian Bioscience Inc in Q3 2021 and held it in 3 quarters.
  • Hudson Edge Investment Partners's Meridian Bioscience Inc position peaked at $756K in Q4 2021.
  • 216 funds tracked by Wall St. Rank held Meridian Bioscience Inc as of Q2 2022.

Based on Hudson Edge Investment Partners's 13F filing for Q2 2022, filed 29 Jul 2022.